Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy

Drug Delivery and Translational Research

Volumn 2, Issue 6, 2012, Pages 418-436

  Aravind, Athulya ^a   Yoshida, Yasuhiko ^a   Maekawa, Toru ^a   Kumar, D Sakthi ^a  

^a TOYO UNIVERSITY   (Japan)

Author keywords

Antibodies; Aptamers; Cancer therapy; Nanoparticles; Polymers; Targeted Drug delivery

Indexed keywords

A 30; AGATOLIMOD; ANTINEOPLASTIC AGENT; ARC 245; AS 1411; CLONE 5; D 4; D 60; IMO 2055; MUC 1 TR 1 4; NANOPARTICLE; ODN 2006; PACLITAXEL; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR BB; POLYMER; TTA 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR; XPSM A10; XPSM A9;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BIOCOMPATIBILITY; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SURFACE PROPERTY;

EID: 84869021184     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0104-0     Document Type: Review

References (180)

1. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008; 26: 442-9.
2. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; 2: 1696-702.
3. Zhang L, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008; 83: 761-9.
4. Brewer E, Coleman J and Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J. Nanomaterials. 2011; 2011. doi: 10. 1155/2011/408675.
5. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002; 6: 319-27.
6. Chiellini E, Solaro R. Biodegradable polymeric materials. Adv Mater. 1996; 8: 305-13.
7. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery devices. New York: Marcel Dekker; 1990. p. 1-41.
8. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. Nature. 1997; 388: 860-2.
9. Gref R, Luck M, Quellec P, et al. Steakth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influence of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B. 2000; 18: 301-13.
10. Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials. 2000; 21: 1659-68.
11. Grayson ACR, Cima MJ, Langer R. Size and temperature effects on poly (lactic-co-glycolic acid) degradation and microreservoir device performance. Biomaterials. 2005; 26: 2137-45.
12. Reed AM, Gilding DK. Biodegradable polymers for use in surgeryopoly(glycolic)/poly(lactic acid) homo and copolymers: 2. In vitro degradation. Polymer. 1981; 22: 494-8.
13. Vincent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006; 24: 39-47.
14. Cerchia L, de Franciscis V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010; 28: 517-25.
15. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 2007; 14: 283-91.
16. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest. 2000; 106: 923-38.
17. Wang KY, et al. A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry. 1993; 32: 1899-904.
18. Fang X, Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res. 2010; 43: 48-57.
19. Osborne SE, Ellington AD. Nucleic acid selection and the challenge of combinatorial chemistry. Chem Rev. 1997; 97: 349-70.
20. Osborne SE, Matsumura I, Ellington AD. Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr Opin Chem Biol. 1997; 1: 5-9.
21. Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev. 2007; 107: 3715-43.
22. Navani NK, Li Y. Nucleic acid aptamers and enzymes as sensors. Curr Opin Chem Biol. 2006; 10: 272-81.
23. Bunka DH, Stockley PG. Aptamers come of ages at last. Nat Rev Microbiol. 2006; 4: 588-96.
24. Farokhzad OC, Jon S, Langer R. Aptamers and cancer nanotechnology. In: Amiji MM, editor. Nanotechnology for cancer therapy. Boca Raton: Taylor & Francis Group; 2006. pp. 289-313.
25. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitrous humor of rhesus monkeys. Pharm Res. 2000; 17: 1503-10.
26. Fitzwater T, Polisky BA. SELEX primer. Methods Enzymol. 1996; 267: 275-301.
27. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest. 2000; 106: 929-34.
28. Huang DB, et al. Crystal structure of NF-kB (p50)2 complexed to a high-affinity RNA aptamer. Proc Natl Acad Sci USA. 2003; 100: 9268-73.
29. Girvan AC, et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006; 5: 1790-9.
30. Zhang L, Radovic-Moreno AF, Alexis F, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem. 2007; 2: 1268-71.
31. Charlton J, Sennello J, Smith D. In vivo imagining of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol. 1997; 4: 809-16.
32. Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie. 2005; 87: 921-30.
33. Herr JK, et al. Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem. 2006; 78: 2918-24.
34. Lee JH, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA. 2005; 102: 18902-7.
35. Green LS, et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol. 1995; 2: 683-95.
36. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related mascular degeneration. N Engl J Med. 2004; 351: 2805-16.
37. Vinores SA. Technology evalution pegaptanib. Eyetech/Pfizer. Curr Opin Mol Ther. 2003; 5: 673-9.
38. Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother. 2005; 6: 1421-3.
39. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818-22.
40. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249: 505-10.
41. Taghdisi SM, Lavaee P, Ramezani M, Abnous K. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur J Pharm Biopharm. 2011; 77: 200-6.
42. Aptamers JW. In: Meyers RA, editor. Encyclopedia in analytical chemistry. Chichester: Wiley; 2000. p. 4848-71.
43. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010; 50: 237-57.
44. Vater A, Klussmann S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr Opin Drug Discov Dev. 2003; 6: 253-61.
45. Eulberg D, Klussmann S. Spiegelmers: biostable aptamers Chem. Biochem. 2003; 4: 979-83.
46. Schmidt KS, Borkowski S, Kurreck J, et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 2004; 32: 5757-65.
47. Tucker CE, Chen LS, Judkins MB, et al. Detection and plasma pharmacokinetics of an anto-vascular endothelial growth factor oligonucleotides-aptamer (NX1838) in rhesus monkeys. J Chromatogr B: Biomed Sci Appl. 1999; 732: 203-12.
48. Ozalp VO and Schafer J. Aptamer-nanoparticle bioconjugates for drug delivery. In: Hashim AA, editor. The delivery of nanoparticles. 2012; doi: 10. 5772/35188.
49. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002; 8: 1172-81.
50. Hong K, Kirpotin DB, Park JW, et al. Anti-HER2 immunoliposomes for targeted drug delivery. Ann NY Acad Sci. 1999; 886: 293-6.
51. de Menezes DE L, Pilarski LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta. 2000; 1466: 205-20.
52. de Menezes DE L, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B cell Lymphoma. Cancer Res. 1998; 58: 3320-30.
53. Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Mater Today. 2005; 5: 18-26.
54. Huang G, Gao J, Hu Z. Controlled drug release from hydrogel nanoparticle networks. J Control Release. 2004; 94: 303-11.
55. Gao J, Niklason L, Zhao XM, Langer R. Surface modification of polyanhydride microspheres. J Pharm Sci. 1998; 87: 246-8.
56. Sommerfeld P, Sabel BA, Schroeder U. Long term stability of PBCA nanoparticle suspensions. J Microencapsul. 2000; 17: 69-79.
57. Molpeceres J, Chacon M, Guzman M, et al. A polycapro-lactone nanoparticle formulation of cyclosporine-A improves the prediction of area under the curve using a limited sampling strategy. Int J Pharm. 1999; 187: 101-13.
58. Alonso MJ, Gupta RK, Min C, et al. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine. 1994; 12: 299-306.
59. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 2002; 233: 51-9.
60. Deng JS, Li L, Tian Y, et al. In vitro characterization of poly orthoester microparticles containing bupivacaine. Pharm Dev Technol. 2003; 8: 31-8.
61. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997; 28: 5-24.
62. Matsusue Y, Hanafusa S, Yamamuro T, et al. Tissue reaction of bioabsorbable ultra high strength poly(L-lactide)rod. A long term study in rabbits. Clin Orthop Relat Res. 1995; 317: 246-53.
63. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005; 26: 2713-22.
64. Thamake SI, Raut SL, Ranjan AP, et al. Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology. 2011; 22: 035101.
65. Tong R, Yala L, Fan TM, Cheng J. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials. 2010; 31: 3043-53.
66. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54: 631-51.
67. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998; 95: 4607-12.
68. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999; 59: 4129-35.
69. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size-dependence and cut-off size. Cancer Res. 1995; 55: 3752-6.
70. Sledge Jr GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003; 39: 1668-75.
71. Teicher BA. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist Updat. 2000; 3: 67-73.
72. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65: 271-84.
73. Moghimi SM. Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. Adv Drug Deliv Rev. 1995; 17: 103-15.
74. Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta. 1992; 1104: 95-101.
75. Rejman J, Oberle V, Zuhorn IS, et al. Size-dependent internalization of particles via the pathways of clathrinand caveolae-mediated endocytosis. Biochem J. 2004; 377: 159-69.
76. Koval M, Prieter K, Adles C, et al. Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res. 1998; 242: 265-73.
77. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010; 145: 182-95.
78. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006; 103: 6315-20.
79. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 64: 7668-72.
80. Jaffar S, Nam KT, Khademhosseini A, et al. Layer-by-layer surface modification and patterned electrodeposition of quantum dots. Nano Lett. 2004; 4: 1421-5.
81. Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extra vascular compartments of tumors. Cancer Res. 2002; 62: 6831-6.
82. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976; 263: 797-800.
83. Gref R, Minamitake Y, Peracchia MT, et al. Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration, Pharm. Biotechnol. 1997; 10: 167-98.
84. Lemarchand C, Gref R, Couvrneur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004; 58: 327-41.
85. Lemarchand C, Gref R, Passirani C, et al. Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials. 2006; 27: 108-18.
86. Weissleder R, Kelly K, Sun EY, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005; 23: 1418-23.
87. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Review of animal and human studies. Clin Pharmacokinet. 2003; 42: 419-36.
88. Mosqueira VC, Legrand P, Morgat JL, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res. 2001; 18: 1411-9.
89. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science. 1994; 263: 1600-3.
90. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007; 28: 869-76.
91. Sehgal D, Vijay IK. A method for the high efficiency of water-soluble carbodiimide-mediated amidation. Anal Biochem. 1994; 218: 87-91.
92. Aravind A, Varghese SH, Veeranarayanan S, et al. Aptamer-labeled PLGA nanoparticles for targeting cancer cells. Cancer Nano. 2012. doi 10. 1007/s12645-011-0024-6.
93. Nair BG, Nagaoka Y, Morimoto H, et al. Aptamer conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology. 2010; 21: 455102-10.
94. Lü J, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9: 325-41.
95. Lavik EB, Hrkach JS, Lotan N, et al. A simple synthetic route to the formation of a block copolymer of poly (lactic-co-glycolic acid) and polylysine for the fabrication of functionalized, degradable structures for biomedical applications. J Biomed Mater Res. 2001; 58: 291-4.
96. Caponetti G, Hrkach JS, Kriwet B, et al. Microparticles of novel branched copolymers of lactic acid and amino acids: preparation and characterization. J Pharm Sci. 1999; 88: 136-41.
97. Faraasen S, Voros J, Csucs G, et al. Ligand-specific targeting of microspheres to phagocytes by surface modification withpoly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm Res. 2003; 20: 237-46.
98. Zheng J, Hornsby PJ. Production of microspheres with surface amino groups from blends of poly(lactide-co-glycolide) and poly(epsilon-CBZ-L-lysine) and use for encapsulation. Biotechnol Program. 1999; 15: 763-7.
99. Keegan ME, Falcone JL, Leung TC, et al. Biodegradable microspheres with enhanced capacity for covalently bound surface ligands. Macromolecules. 2004; 37: 9779-984.
100. Muller M, Vörös J, Csúcs G, et al. Surface modification of PLGA microspheres. J Biomed Mater Res A. 2003; 66: 55-61.
101. Park A, Wu B, Griffith LG. Integration of surface modification and 3D fabrication techniques to prepare patterned poly (l-lactide) substrates allowing regionally selective cell adhesion. J Biomater Sci Polym Ed. 1998; 9: 89-110.
102. Croll TI, O'Connor AJ, Stevens GW, et al. Controllable surface modification of poly(lactic-co-glycolic acid) (PLGA) by hydrolysis or aminolysis I: physical, chemical, and theoretical aspects. Biomacromolecules. 2004; 5: 463-73.
103. Cao Y, Croll TI, Cooper-White J, et al. Production and surface modification of polylactide-based polymeric scaffolds for soft-tissue engineering. Methods Mol Biol. 2004; 238: 87-112.
104. Yang J, Wan Y, Yang J, et al. Plasma-treated, collagen anchored polylactone: its cell affinity evaluation under shear or shear-free conditions J. Biomed Mater Res. 2003; 67A: 1139-47.
105. Wan YQ, Qu X, Bei JZ, et al. Characterization of surface property of poly(lactide-co-glycolide) after oxygen plasma treatment. Biomaterials. 2004; 25: 4777-83.
106. Orava EW, Cicmil N, Gariépy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta. 2010; 1798: 2190-200.
107. Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem. 2006; 45: 8149-52.
108. Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009; 37: 866-76.
109. Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 2009; 10: 862-8.
110. Willner D, Trail PA, Hofstead SJ, et al. (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem. 1993; 4: 521-7.
111. Chu TC, Marks III JW, Lavery LA, et al. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006; 66: 5989-92.
112. McCauley TG, Hamaguchi N, Stanton M. Aptamer-based biosensor arrays for detection and quantification of biological macromolecules. Anal Biochem. 2003; 319: 244-50.
113. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med. 2006; 47: 668-78.
114. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence. 2010; 1: 4.
115. Chu TC, et al. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron. 2006; 21: 1859-66.
116. McNamara JO, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24: 1005-15.
117. Huang CC, et al. Aptamer-modified gold nanoparticles for colorimetric determination of platelet-derived growth factors and their receptors. Anal Chem. 2005; 77: 5735-41.
118. Chen T, Shukoor MI, Wang R, Zhao Z, Yuan Q, Bamrungsap S, et al. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano. 2011; 5(10): 7866-73.
119. Willis MC, et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem. 1998; 9: 573-82.
120. Estevez CM, Huang Y-F, Kang H, O'Donoghue MB, Bamrungsap S, Yan J et al. 2010 Nanoparticle-aptamer conjugates for cancer cell targeting and detection. In: Grobmyer SR, Moudgil BM, editors. Cancer nanotechnology, methods in molecular biology. p. 624, doi: 10. 1007/978-1-60761-609-2_16.
121. Aravind A, Veeranarayanan S, Poulose AC, Nair R, Nagaoka Y, Yoshida Y, et al. Aptamer-functionalized silica nanoparticles for targeted cancer therapy. Bio Nano Sci. 2012; 2: 1-8.
122. Bagalkot V, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007; 7: 3065-70.
123. Maehashi K, et al. Label-free protein biosensor based on aptamer-modified carbon nanotube field-effect transistors. Anal Chem. 2007; 79: 782-7.
124. Fan Z, Shelton M, Singh AK, et al. Multifunctional plasmonic shell-magnetic core nanoparticles for targeted diagnostics, isolation, and photothermal destruction of tumor cells. ACS Nano. 2012; 6: 1065-73. doi: 10. 1021/nn2045246.
125. Pangburn TO, Petersen MA, Waybrant B, et al. Peptide- and aptamer- functionalized nanovectors for targeted delivery of therapeutics. J Biomech Eng. 2009; 131: 0740051-07400520.
126. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Bio. 2006; 10: 282-9.
127. Murphy GP, Elgamal AA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998; 83: 2259-69.
128. Farokhzad OC, Khademhosseini A, Jon S, et al. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem. 2005; 77: 5453-9.
129. Tong R, Coyle VJ, Tang L, et al. Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications. Micro Res Technol. 2010; 73: 901-9.
130. Janat-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M, et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther. 2004; 9: 829-36.
131. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol. 2009; 27: 643-51.
132. Dong X, Liu A, Zer C, Feng J, Zhen Z, Yang M, et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer. 2009; 9: 133-42.
133. Kim E, Jung Y, Choi H, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 2010; 31: 4592-9.
134. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA. 2008; 105: 17356-61.
135. Dhar S, Kolishetti N, Lippard SJ and Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 2012. doi: 10. 1073/pnas. 1011379108.
136. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res. 2011; 44: 1123-34.
137. Farrell D, Ptak K, Nicholas J, et al. Nanotechnology-based cancer therapeutics-promise and challenge-lessons learned through the NCI alliance for nanotechnology in cancer. Pharm Res. 2011; 28: 273-8.
138. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA. 2008; 105: 2586-91.
139. Fujiyama J, Nakase Y, Osaki K, et al. Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J Control Release. 2003; 89: 397-408.
140. Avgoustakis K, Beletsi A, Panagi Z, et al. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 2002; 79: 123-35.
141. Avgoustakis K, Beletsi A, Panagi Z, et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm. 2003; 259: 115-27.
142. Stolnik S, et al. Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target. 2001; 9: 361-78.
143. Moreno D, et al. Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm. 2008; 68: 503-12.
144. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm. 2007; 67: 1-8.
145. Kolishetti N, Dhar S, Valencia PM, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA. 2010; 107: 17939-44.
146. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011; 32: 8010-20.
147. Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30: 1627-34.
148. Wang AZ, Yuet K, Zhang LF, et al. ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine. 2010; 5: 361-8.
149. Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012; 6: 696-704.
150. Ferreira CS, et al. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol. 2006; 27: 289-301.
151. Yu C, Hu Y, Duan J, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One. 2011; 6: e24077.
152. Weinstein JN, van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 1992; 52: 2747-51.
153. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release. 2001; 74: 7-25.
154. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-57.
155. Less JR, Skalak TC, Sevick EMC, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 1991; 51: 265-73.
156. Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in solid tumors: a novel mechanism of tumorangiogenesis. Microvasc Res. 1996; 51: 260-72.
157. Folkman J. Tumor angiogenesis. In: Holland JF, Frei III E, Bast Jr RC, Kufe DW, Pollock RE, Weichselbaum RR, editors. Cancer medicine. 5th ed. Ontario: Decker; 2000. p. 132-52.
158. Endrich B, Reinhold HS, Gross JF, Intaglietta M. Tissue perfusion in homogeneity during early tumor growth in rats. J Natl Cancer Inst. 1979; 62: 387-95.
159. Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988; 48: 2641-58.
160. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987; 47: 3039-51.
161. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11: 265-83.
162. Mi J, Zhang X, Giangrande PH, et al. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun. 2005; 338: 956-63.
163. Chen CH, Chernis GA, Hoang VQ, Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA. 2003; 100: 9226-31.
164. Lupold SE, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002; 62: 4029-33.
165. Dapic V, Abdomerovic V, Marrington R, et al. Biophysical and biological properties of quadruplex oligonucleotides. Nucleic Acids Res. 2003; 31: 2097-107.
166. Barnhart KM, Laber DA, Bates PJ et al. AGRO100: the translation from lab to clinic of a tumor targeted nucleic acid aptamer. In Proceedings from the American Society for Clinical Oncology, New Orleans, 2004.
167. Laber DA, Sharma VR, Bhupalam L et al. In update on the first phase I study of AGRO100 in advanced cancer. American Society of Clinical Oncology Annual Meeting, Abstract 3064; 2005.
168. Jeong S, Eom T, Kim S, et al. In vitro selection of the RNA aptamer against Sialyl Lewis X and its inhibition of the cell adhesion. Biochem Biophys Res Commun. 2001; 281: 237-43.
169. Santulli-Marotto S, Nair SK, Rusconi C, et al. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 2003; 63: 7483-9.
170. Shangguan D, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA. 2006; 103: 11838-43.
171. Xiao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry. 2008; 14: 1769-75.
172. Daniels DA, et al. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA. 2003; 100: 15416-21.
173. Hicke BJ, Marion C, Chang YF, et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem. 2001; 276: 48644-54.
174. Blank M, Weinschenk T, Priemer M, et al. Systemic evolution of a DNA aptamer binding to rat brain tumor microvessels, selective targeting of endothelial regulatory protein pigpen. J Biol Chem. 2001; 276: 16464-8.
175. Green LS, et al. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry. 1996; 35: 14413-24.
176. Zhou C, et al. Detection of oncoprotein platelet-derived growth factor using a fluorescent signaling complex of an aptamer and TOTO. Anal Bioanal Chem. 2006; 384: 1175-80.
177. Burmeister P, et al. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem Biol. 2005; 12: 25-33.
178. Ruckman J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998; 273: 20556-67.
179. Cerchia L, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 2005; 3: e123.
180. Pashenkov M, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006; 24: 5716-24.